OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Moore on the Prevalence of Ovarian Cancer

July 29th 2020

Kathleen Moore, MD, discusses the current prevalence of ovarian cancer.

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer

July 29th 2020

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Dr. Raje on the Effectiveness of Quadruplet Therapies in Multiple Myeloma

July 29th 2020

Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

July 29th 2020

R. Lor Randall, MD, FACS, discusses preoperative radiotherapy and how it has become a standard of care for patients with soft tissue sarcoma of the extremities; however, postoperative radiation still plays a role in the paradigm, especially when wound risks are considered to be precarious.

Dr. Gandara on Measuring TMB in NSCLC

July 28th 2020

David R. Gandara, MD, discusses measuring tumor mutational burden in patients with non–small cell lung cancer who received prior immunotherapy.

Dr. Kelly on Preliminary Data With Neoadjuvant Immunotherapy in Lung Cancer

July 28th 2020

Karen Kelly, MD, discusses encouraging preliminary data with neoadjuvant immunotherapy in lung cancer.

Dr. Braun on Unanswered Questions With PD-1 Blockade in Advanced RCC

July 28th 2020

David A. Braun, MD, PhD, discusses unanswered questions regarding the utility of PD-1 blockade in advanced renal cell carcinoma.

Dr. Palmer on the Incidence of Graft-Versus-Host Disease

July 28th 2020

Jeanne M. Palmer, MD, discusses the prognosis and challenges of predicting graft-versus-host disease in patients who have undergone transplant.

Dr. Gafita on the Opportunity for 177Lu-PSMA-617 in mCRPC

July 28th 2020

Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.

Dr. Roland on Neoadjuvant Checkpoint Blockade in Sarcoma Subtypes

July 28th 2020

Christina L. Roland, MD, PhD, discusses the design of a randomized, phase 2 trial with nivolumab and ipilimumab in resectable retroperitoneal dedifferentiated liposarcoma, as well as radiation therapy in extremity/truncal undifferentiated pleomorphic sarcoma.

Dr. Zakashansky on Maintenance Olaparib in Relapsed BRCA1/2+ Ovarian Cancer

July 28th 2020

Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

July 28th 2020

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the prognosis of patients with melanoma brain and/or central nervous system metastases.

Dr. Lenz on Later-Line Combo Approaches in CRC

July 28th 2020

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.

Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC

July 24th 2020

Martin Reck, MD, PhD, discusses safety data from the phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Dr. Ramalingam on Next Steps With Nivolumab/Ipilimumab in NSCLC

July 24th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Dr. Ahn on Limitations of Targeted Therapy in CRC

July 24th 2020

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Dr. Shafique on the Goal of the CLASSICAL-Lung Trial With Pepinemab/Avelumab in NSCLC

July 24th 2020

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL Models

July 24th 2020

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer

July 24th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Dr. Chandra on Unanswered Questions With Targeted Therapy in Melanoma

July 24th 2020

Sunandana Chandra, MD, MS, discusses unanswered questions regarding the utility of targeted therapy in melanoma.